Graft versus Host Disease: From Basic Pathogenic Principles to DNA Damage Response and Cellular Senescence

Kuba, Adam; Raida, Ludek

doi:10.1155/2018/9451950

Cited by 29 publications

(23 citation statements)

References 136 publications

(145 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the immune system employs apoptosis not only as a self-restricting regulatory mechanism but also as an effector mechanism of immune-competent cells which can selectively eliminate virus-infected, transformed cells [111], and also normal cells in case of autoimmune inflammation [97], or in post-transplantion disorders [112]. TRAIL also represents an effector of immune-surveillance function and contribute to apoptosis of tumor and virus-infected cells [84].…”

Section: The Impact Of Central and Peripheral Inflammatory/ Immune Rementioning

confidence: 99%

The immune system on the TRAIL of Alzheimer’s disease

Burgaletto

Munafò

Benedetto

et al. 2020

J Neuroinflammation

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most common form of dementia, characterized by progressive degeneration and loss of neurons in specific regions of the central nervous system. Chronic activation of the immune cells resident in the brain, peripheral immune cell trafficking across the blood-brain barrier, and release of inflammatory and neurotoxic factors, appear critical contributors of the neuroinflammatory response that drives the progression of neurodegenerative processes in AD. As the neuro-immune network is impaired in course of AD, this review is aimed to point out the essential supportive role of innate and adaptive immune response either in normal brain as well as in brain recovery from injury. Since a fine-tuning of the immune response appears crucial to ensure proper nervous system functioning, we focused on the role of the TNF superfamily member, TNF-related apoptosis-inducing ligand (TRAIL), which modulates both the innate and adaptive immune response in the pathogenesis of several immunological disorders and, in particular, in AD-related neuroinflammation. We here summarized mounting evidence of potential involvement of TRAIL signaling in AD pathogenesis, with the aim to provide clearer insights about potential novel therapeutic approaches in AD.

show abstract

Section: The Impact Of Central and Peripheral Inflammatory/ Immune Rementioning

confidence: 99%

The immune system on the TRAIL of Alzheimer’s disease

Burgaletto

Munafò

Benedetto

et al. 2020

J Neuroinflammation

View full text Add to dashboard Cite

show abstract

“…Graft-versus-host disease (GVHD) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs due to the presence of donor's immunocompetent cells; this condition is considered a major obstacle of HSCT avoiding successful treatment of hematological diseases; that is why novel approaches such as MSCs to overcome this challenge must be considered [ 107 , 108 ].…”

Section: Current Mesenchymal Stem Cell Research For Clinical Applimentioning

confidence: 99%

Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2

Juárez-Navarro

Padilla-Camberos

Díaz

et al. 2020

Stem Cells International

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs), defined as plastic adherent cells with multipotent differentiation capacity in vitro, are an emerging and valuable tool to treat a plethora of diseases due to their therapeutic mechanisms such as their paracrine activity, mitochondrial and organelle transfer, and transfer of therapeutic molecules via exosomes. Nowadays, there are more than a thousand registered clinical trials related to MSC application around the world, highlighting MSC role on difficult-to-treat high-incidence diseases such as the current COVID-19, HIV infections, and autoimmune and metabolic diseases. Here, we summarize a general overview of MSCs and their therapeutic mechanisms; also, we discuss some of the novel clinical trial protocols and their results as well as a comparison between the number of registries, countries, and search portals.

show abstract

“…The pathophysiology of GvHD happens in several phases with the initial phase beginning due to the damaged intestinal epithelium by the conditioning regimens ( Figure 1 a). The loose intestinal integrity after conditioning allows the release of intestinal microbes, pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and pro-inflammatory cytokines to cross the epithelial barrier and enter the blood circulation [ 39 , 40 , 41 ]. Subsequently, translocation of these pathogenic components activates APCs by triggering toll-like receptor (TLR) signaling pathways ( Figure 1 b) [ 42 , 43 , 44 ].…”

Section: Pathogenesis Of Acute Graft-versus-host Diseasementioning

confidence: 99%

Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia

Kim

Santhanam²,

Lim

et al. 2020

IJMS

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the main therapeutic strategy for patients with both malignant and nonmalignant disorders. The therapeutic benefits of allo-HSCT in malignant disorders are primarily derived from the graft-versus-leukemia (GvL) effect, in which T cells in the donor graft recognize and eradicate residual malignant cells. However, the same donor T cells can also recognize normal host tissues as foreign, leading to the development of graft-versus-host disease (GvHD), which is difficult to separate from GvL and is the most frequent and serious complication following allo-HSCT. Inhibition of donor T cell toxicity helps in reducing GvHD but also restricts GvL activity. Therefore, developing a novel therapeutic strategy that selectively suppresses GvHD without affecting GvL is essential. Recent studies have shown that inhibition of histone deacetylases (HDACs) not only inhibits the growth of tumor cells but also regulates the cytotoxic activity of T cells. Here, we compile the known therapeutic potential of HDAC inhibitors in preventing several stages of GvHD pathogenesis. Furthermore, we will also review the current clinical features of HDAC inhibitors in preventing and treating GvHD as well as maintaining GvL.

show abstract

Graft versus Host Disease: From Basic Pathogenic Principles to DNA Damage Response and Cellular Senescence

Cited by 29 publications

References 136 publications

The immune system on the TRAIL of Alzheimer’s disease

The immune system on the TRAIL of Alzheimer’s disease

Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2

Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia

Contact Info

Product

Resources

About